US 12,109,266 B2
Modulating gabarap to modulate immunogenic cell death
Kenneth C. Anderson, Wellesley, MA (US); and Annamaria Gullà, Boston, MA (US)
Assigned to DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US)
Filed by Dana-Farber Cancer Institute, Inc., Boston, MA (US)
Filed on Nov. 3, 2021, as Appl. No. 17/518,272.
Claims priority of provisional application 63/113,284, filed on Nov. 13, 2020.
Prior Publication US 2022/0211848 A1, Jul. 7, 2022
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61P 35/04 (2006.01); C07K 16/28 (2006.01)
CPC A61K 39/39558 (2013.01) [A61P 35/04 (2018.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); A61K 2039/572 (2013.01); C07K 2317/21 (2013.01); C07K 2317/52 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01)] 10 Claims
 
1. A method of identifying a compound that induces immunogenic cell death (ICD) of a multiple myeloma cancer cell comprising an increase in an amount of STC1, wherein the STC1 comprises an amino acid sequence of SEQ ID NOs: 14, 16, or 18, the method comprising:
a) contacting the multiple myeloma cancer cell comprising an increase in the amount of STC1, relative to the amount of STC1 in a non-cancerous cell, with (i) a test compound and (ii) an inducer of ICD; and
b) determining the level of calreticulin trapped in the mitochondria of the multiple myeloma cancer cell, wherein the decrease in the level of calreticulin trapped in the mitochondria of the multiple myeloma cancer cell in the presence of the test compound as compared to the level of calreticulin trapped in the mitochondria of the multiple myeloma cancer cell in the absence of the test compound indicates that the test compound induces ICD of the multiple myeloma cancer cell comprising the increase in the amount of STC1.